NEW YORK, NY — May 6, 2026 — HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on IndyGeneUS Bio, recognizing the company as a leader in representative genomic intelligence and a pioneer of a new category in medicine: the Representative Genomic Biorepository.

The independent evaluation draws on 48 peer-reviewed and verifiable sources across eight domains—scientific, regulatory, commercial, national security, operational, legal, sovereign health, and technology—concluding that a structural gap in genomic data is limiting the effectiveness of modern medicine and global health systems. “The convergence of peer-reviewed science, regulation, capital markets, and operational readiness reflects a level of maturity rarely seen at this stage,” said Stan Kachnowski, PhD, MPA, Chair of HITLAB.

According to the report, 88% of human biology remains underrepresented in existing genomic databases, creating systemic inefficiencies across drug development, diagnostics, and AI-driven healthcare models. This gap has direct consequences:

• Reduced drug efficacy across global populations
• Inaccurate risk prediction models
• Billions in redundant R&D spend
• Missed opportunities for breakthrough discovery

IndyGeneUS Bio has developed the first Representative Genomic Biorepository, purpose- built to correct this imbalance at scale.
“Modern medicine has been solving for a fraction of humanity—while calling it universal. Eighty-eight percent of human biology has been missing from the data that drives how we diagnose, treat, and develop therapies. That absence doesn’t just limit discovery—it defines it. We built the Representative Genomic Biorepository to correct that foundation—bringing the missing 88% into the science itself, so precision medicine can finally operate with the accuracy it promises. This is no longer a future state. The data exists. The infrastructure is built. And the path forward is clear.” — Yusuf Henriques, Founder & CEO, IndyGeneUS Bio

The company holds over 1 million verified whole-blood records from underrepresented populations through exclusive agreements spanning South Africa and Nigeria, forming one of the most comprehensive and representative genomic datasets available for sequencing today. This dataset introduces millions of previously unobserved genetic variants—unlocking new pathways for drug discovery, improving diagnostic precision, and strengthening global biodefense systems.

HITLAB’s findings position IndyGeneUS Bio at the intersection of multiple accelerating forces:

• Regulatory Momentum: New FDA and global standards are mandating diverse datasets in drug development
• Commercial Demand: Billions in pharmaceutical capital are actively seeking access to representative genomic data
• National Security Needs: Policy shifts have created an urgent demand for compliant, domestic genomic infrastructure
• Technological Readiness: The company’s platform is already validated in live global health deployments

The Representative Genomic Biorepository directly addresses disease markets exceeding $900 billion globally, including oncology, cardiovascular disease, neurodegenerative disorders, and metabolic conditions.

“For too long, entire populations have been left out of the data that shapes how we diagnose, treat, and ultimately care for people. This isn’t just a scientific gap—it’s a human one. What we’re building is about making sure no one is invisible in the future of medicine. When the data reflects all of us, the solutions become stronger, the outcomes become better, and the system begins to work the way it was always meant to—fairly and effectively for everyone. That’s the impact we’re committed to.” — Angel N. Livas, Co-Founder & Chief Communications Officer, IndyGeneUS Bio

As precision medicine and AI-driven discovery accelerate, access to representative data is emerging as one of the most valuable assets in healthcare—impacting not just underserved populations, but improving outcomes for all patients.